Image

Role of Pro-Resolving Lipid Mediators in Obesity-Associated Diseases

Role of Pro-Resolving Lipid Mediators in Obesity-Associated Diseases

Recruiting
Female
Phase N/A

Powered by AI

Overview

The main objective of this project is to determine the possible association between the levels of certain bioactive lipids, which the body produces from dietary fatty acids, and tumor characteristics in breast cancer patients, as well as their relationship with overweight/obesity.

Specific objectives are:

  • To analyse anthropometric and body composition changes.
  • To evaluate physical activity level.
  • To determine dietary profile.
  • To determine the adherence to Mediterranean dietary pattern.
  • To assess the quality of life.
  • To determine levels of specialized pro-resolving lipid mediators

The target sample size is 60 subjects. Participants will be allocated in four groups:

  • Group 1: Postmenopausal healthy women with overweight/obesity (n=15)
  • Group 2: Postmenopausal healthy women with normoweight (n=15)
  • Group 3: Postmenopausal women with breast cancer and overweight/obesity (n=15)
  • Group 4: Postmenopausal women with breast cancer and normoweight (n=15)

Description

Volunteers who wish to participate in the study will be informed about the procedures of the study. Volunteers who agree to participate will sign the informed consent form.

Participants from Group 1 and Group 2 will visit nutritional intervention unit at Clinical Investigation Day 1 (day 1) and at Clinical Investigation Day 2 (day 8).

Participants from Group 3 and Group 4 will visit nutritional intervention unit after surgery for tumor removal, at Clinical Investigation Day 1 (day 1), at Clinical Investigation Day 2 (day 8), at Clinical Investigation Day 3 (1 year) and at Clinical Investigation Day 4 (1 year + day 8).

  • Clinical Investigation Day 1 and 3: anthropometric and body composition measurements, delivery of questionnaires , blood extraction, placement of accelerometer .
  • Clinical Investigation Day 2 and 4: reception of accelerometer and collection of completed questionnaires.

Eligibility

HEALTHY PARTICIPANTS:

Inclusion Criteria:

  • Postmenopause (al least 1 year).
  • Normoweight or overweight/obesity.
  • No personal history of cancer.
  • Stable weight over the last 3 months (±5%).
  • Willing to sign the informed consent and comply with all study procedures.

Exclusion Criteria:

  • Personal history of cancer.
  • Current weight loss treatment (diet, supplementation, surgery, others...).
  • Bariatric surgery.
  • No stable pharmacological treatment for at least 3 months.
  • Diabetes treatment and hormone replacement therapy.
  • Relevant functional or structural abnormalities of the gastrointestinal tract, such as malformations, angiodysplasias, active peptic ulcers, chronic inflammatory or malabsorption diseases, hiatal hernia, chronic reflux, etc.
  • High alcohol intake, more than 14 units per week for women and 20 units per week for men.
  • Surgical interventions resulting in permanent sequelae of the gastrointestinal tract.
  • Liver disease, except for non-alcoholic fatty liver disease.
  • Cognitive and/or psychiatric impairment.
  • Poor compliance or difficulty following study procedures.

BREAST CANCER PARTICIPANTS:

Inclusion Criteria:

  • Postmenopause (at least 1 year).
  • Normoweight or overweight/obesity.
  • Luminal subtype breast cancer, stages I-II, who require tumor resection and do not require preoperative treatment.
  • Willing to sign the informed consent and comply with all study procedures.

Exclusion Criteria:

  • Luminal subtype breast cancer stages over than II or other type of breast cancer.
  • Require preoperative treatment.

Study details
    Breast Cancer
    Health
    Subjective
    Obesity

NCT07447440

Clinica Universidad de Navarra, Universidad de Navarra

13 May 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.